News & Views | Published:

Raloxifene: Magic bullet for heart and bone?

Nature Medicinevolume 4pages152153 (1998) | Download Citation


Clinical results show that raloxifene benefits heart and bone in postmenopausal women without increasing the risk of uterine cancer but its long-term effects are unknown.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Hammond, G.B. Menopause and hormone replacement therapy: An overview. Obstet. Cynecol. 87, 2–15 (1995)

  2. 2

    Sato, M., Rippy, M.K. & Bryant, H.U. Raloxifene, tamoxifen, nafoxidine or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10, 905–912 (1996)

  3. 3

    Ward, R.L. et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner. 22, 87–94 (1993).

  4. 4

    Black, L.J. et al. Raloxifene (LY1 39481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Gin. Invest. 93, 63–69 (1994).

  5. 5

    Delmas, P.D. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641–1647 (1997).

  6. 6

    Scharf, M.B. et al. Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study. Clinical Therapeutics 19, 304–311 (1997).

  7. 7

    Bergman, A., Karram, M.M. & Bhatia, N.N. Changes in urethral cytology following estrogen administration. Gynecologic & Obstetric Investigation 29, 211–213 (1990).

  8. 8

    Henderson, V.W. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 48, 27–35 (1997)

  9. 9

    Meisel, R.L. et al. Antagonism of sexual behavior in female rats by ventromedial hypothalamic implants of antiestrogen. Neuroendocrinology 45, 201–207 (1987).

  10. 10

    Kuiper, G.G. & Gustafsson, J.-Å. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and antiestrogens. FEBS Letts. 410, 87–90 (1997).

  11. 11

    Paech, K. et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP-1 sites). Science 277, 1508–1510 (1997).

  12. 12

    Brzozowski, A.M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758 (1997)

Download references

Author information


  1. Department of Medical Nutrition and Department of Biosciences, Karolinska Institute, NOVUM

    • Jan-ÅKe Gustafsson


  1. Search for Jan-ÅKe Gustafsson in:

About this article

Publication history

Issue Date


Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing